Clinical outcomes of venetoclax combined with hypomethylating agents versus hypomethylating agents alone in <i>TP53</i>-mutated myelodysplastic syndromes
Authors
Yu‐Hung Wang (ORCID: https://orcid.org/0000-0003-4483-5627)
Antoine N. Saliba (ORCID: https://orcid.org/0000-0001-5134-7336)
Clinical outcomes of venetoclax combined with hypomethylating agents versus hypomethylating agents alone in TP53-mutated myelodysplastic syndromes
Yu‐Hung Wang, Antoine N. Saliba, Ayalew Tefferi, Cecilia Arana Yi et al.
Journal
Haematologica
Topics
Acute Myeloid Leukemia Research
article
Clinical outcomes of venetoclax combined with hypomethylating agents versus hypomethylating agents alone in TP53-mutated myelodysplastic syndromes
Yu‐Hung Wang, Antoine N. Saliba, Ayalew Tefferi, Cecilia Arana Yi, Aref Al‐Kali, Mohamed A. Kharfan‐Dabaja, Hemant S. Murthy, M. R. Litzow, James M. Foran, Nandita Khera, Hassan B. Alkhateeb, Mrinal M. Patnaik, Talha Badar, Kashish Shah, Mobachir El Kettani, Nathan Punwani, Jeanne Palmer, Naseema Gangat, William Hogan, Mahmood Aldapt, Mithun V. Shah, Lisa Sproat
article en
Abstract
No abstract available for this paper.
Publication Tag
Haematologica
Institutions
Mayo Clinic (US), National Taiwan University (TW), Jacksonville College (US), WinnMed (US), Mayo Clinic in Arizona (US), Mayo Clinic Hospital (US), Mayo Clinic in Florida (US)